Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

surpassing Merck's Keytruda in key outcomes and sending SMMT stock skyrocketing. Like Ivonescimab, Nuvectis Pharma’s (NASDAQ: NVCT) NXP900 tackles resistance in NSCLC but targets a different ...

Eisai and Merck & Co have reported positive data from the LEAP-012 trial for their combination of Lenvima (lenvatinib) and ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...